AB 1887 sets rare disease drug authorization timing
Oct 4, 2026 edition · GC-2026-0246 · Published 2026-10-04 · Version 2 · Final
AB 1887 sets a 30-day backstop and immediate-approval consequence for narrowly qualifying rare-disease drug requests under affected 2027 coverage.
What happened
California approved and filed AB 1887 on September 27. For contracts and policies issued, amended or renewed on or after January 1, 2027, a carrier must complete prior authorization within 30 days of the initial request when the prescription is the only FDA-approved treatment for a rare disease, an appropriate specialist prescribes it and determines it medically necessary. Rare disease means a condition affecting fewer than 200,000 people in the United States. The initial request occurs when the provider or staff sends it to the carrier or its delegate; the statute does not describe the clock as beginning only after a later internal intake milestone.
For a qualifying request, authorization must be immediately approved if no approval or denial decision has been made by the end of 30 days, or if a dispute with the provider or member remains ongoing then. The statute preserves the other referenced authorization timelines, so the 30-day backstop does not displace a faster applicable review obligation. The plan provision excludes Medi-Cal managed care contracts. As of October 4, teams should prepare for affected January renewals by preserving request dates, specialist and sole-approved-treatment support, and the escalation needed to recognize either immediate-approval trigger.
Scope and timing
- Authority status
- Final
- Applicability
- Potentially applicable
- Audience
- Health systems, Provider networks, Health-tech
- Jurisdiction
- California
- Affected functions
- Managed Care, Compliance, Clinical Operations
- Responsible owner
- Managed Care
- Recorded date
- 2027-01-01
- Date type
- implementation
Why it matters
Specialty treatment delays can require a different result once the statutory backstop expires, making accurate request tracking and clinical eligibility documentation essential.
Recommended action
Identify affected 2027 coverage, document specialist expertise and the only-FDA-approved-treatment condition, preserve initial transmission dates, and configure escalation for both 30-day approval triggers.
Implementation playbook
- Confirm affected members, benefits and contracts against the final statutory scope. Managed Care · Due 2026-10-18
- Confirm covered drugs, prescriber expertise and required request content; monitor response timing and escalate delays. Compliance · Due 2027-01-01
- Validate updated workflows, communicate changes and monitor implementing guidance. Compliance · Due 2027-01-01
Sources
- AB1887 enacted final textOfficial · California Legislature · 2026-09-27 · Source review 2026-10-05
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Medicare & Medicaid report →